A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease

Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs RG 6100 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 13 Nov 2017 According to an AC Immune media releaseAC Immune became eligible to receive a milestone payment of CHF 14 million upon the dosing of the first patient of this trial.
    • 07 Nov 2017 According to an AC Immune media release, the first patient has been dosed in this trial.
    • 31 Oct 2017 Planned End Date changed from 30 Nov 2022 to 20 Sep 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top